Program
tusamitamab sonditecan
In Pfizer’s pipeline, CEACAM5-directed antibody-drug conjugate
. Its studies are mostly in Colorectal Neoplasms, led by Pfizer.
Furthest: phase 1, since Nov 9, 20231 company-led study, 1 open or runningNext primary completion: Sep 12, 2029 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 11 open or running | phase 1since Nov 9, 2023 | Nov 9, 2023 | Sep 12, 2029phase 1 · NCT06131840 |
- Named in Pfizer’s own pipeline as
PF-08046050
, phase 1, as of Nov 3, 2026 (source). - Named in sanofi’s own pipeline as
SAR445953
, phase 1, as of Sep 30, 2026 (source).
Also a collaborator on its studies: Sanofi.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 9, 2023First study: phase 1 study in Colorectal NeoplasmsFirst studyNCT06131840 · 914 planned · United States, Canada, China and more
Ahead
- Sep 12, 2029Primary completion: phase 1 study in Colorectal NeoplasmsNCT06131840
TargetBeta
“CEACAM5-directed antibody-drug conjugate”the company's pipeline, read by Claude · source
“CEACAM5-Topo1 ADC”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of tusamitamab, a humanized, immunoglobulin G1-kappa (IgG1k) monoclonal antibody directed against the tumor-associated antigen (TAA) carcinoembryonic antigen (CEA; carcinoembryonic antigen-related cell adhesion molecule 5; CEACAM5; CD66e) and conjugated t…”NCIt, read by Claude
Other programs on CEACAM5
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| precemtabart tocentecanrule | Merck KGaA, Darmstadt, Germany | phase 3 | 4 |
| Anti-CEA/Anti-4-1BB Bispecific Antibody LM-24C5 | Sino Biopharmaceutical | phase 2 | 2 |
| Anti-CEACAM5 Antibody-drug Conjugate BMS-986490rule | Bristol-Myers Squibb | phase 2 | 1 |
| Anti-CEACAM5 Antibody-drug Conjugate IBI3020rule | Innovent Biologics | phase 1 | 1 |
| RO7821657rule | Hoffmann-La Roche | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06131840Colorectal Neoplasms · United States, Canada, China and more | 1 | Recruiting | Sep 12, 2029 | 914 |
How it is read
Names in the registry
- “PF-08046050”, 1 entry
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.